BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB:CAMH), today announced a three-year exclusive sales and marketing agreement with St. Jude Medical, Inc. (NYSE:STJ), under which St. Jude Medical will be responsible for marketing Cambridge Heart’s HearTwave II® Microvolt T-Wave Alternans System and sensors to cardiologists and electrophysiologists in North America. Cambridge Heart’s sales force will continue to market the HearTwave II to internal medicine and primary care practices. Alternans testing is designed to allow physicians to identify patients who are at increased risk of Sudden Cardiac Death (SCD).
